Skip to search formSkip to main contentSkip to account menu

BMS 214662

Known as: BMS-214662, BMS214662, FTI BMS 214662 
A nonsedating benzodiazepine derivative with potential antineoplastic activity. Farnesyltransferase inhibitor BMS-214662 inhibits the enzyme… 
National Institutes of Health

Related topics

Related topics

2 relations
Positive Regulation of Apoptosisprotein farnesyltransferase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Microfluidic radiolabeling of biomolecules with PET radiometals.
2007
2007
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro‐apoptotic activity of interferon‐α through the inhibition of multiple survival pathways
Interferon α (IFNα) induces an EGF‐Ras→Raf‐1→Erk dependent survival pathway counteracting apoptosis induced by the cytokine. In… 
Highly Cited
2005
Highly Cited
2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
PURPOSE To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase… 
2005
2005
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
PURPOSE BMS-214662 is a potent, nonpeptide, small molecule inhibitor of human farnesyltransferase (FT). We have conducted a phase… 
2005
2005
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
Purpose: This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a… 
2005
2005
A comparative study of gamma irradiation of poly(ethylene-co-vinyl acetate) and poly(ethylene-co-vinyl acetate)/carbon black mixture
2005
2005
Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors
Purpose: A phase I trial of BMS-214662, a selective farnesyltransferase inhibitor with significant preclinical antitumor activity… 
Review
2004
Review
2004
Radiation Sensitization by Inhibition of Activated Ras
Background and Purpose:Ras has been identified as a significant contributor to radiation resistance. This article reviews… 
2002
2002
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia
Summary. Combination of STI571, a tyrosine kinase inhibitor, with other drugs may be beneficial in the treatment of chronic… 
2001
2001
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer
The effects of farnesyl:protein transferase inhibitors (FTIs) were evaluated against hormone-dependent and hormone-independent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)